ArticleCancers2024
Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience.
Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 13 citations in OpenAlex.
- The tumor microenvironment in triple negative breast cancer and a strategy to improve responses to immunotherapy using cryoablation and immunostimulants.Cancer biology & therapy · 2026Review
- A multicenter pilot study of nivolumab with drug-eluting bead transarterial chemoembolization in patients with liver-limited hepatocellular carcinoma.ESMO gastrointestinal oncology · 2026Article
- Thermal Ablation for Colorectal Liver Metastases: Current Evidence and Future Horizons.Diagnostics (Basel, Switzerland) · 2026Review
- Thermal modulation enhances antitumour immunity and improves immunotherapy responses in lung cancer.Discover oncology · 2026Review
- Synergistic immunomodulation: integrating physical ablation with immune checkpoint inhibitors for metastatic colorectal carcinoma.Frontiers in immunology · 2026Review
- Integrating cryoablation with immunotherapy in non-small cell lung cancer: mechanisms, clinical evidence, and translational barriers.Frontiers in oncology · 2026Review
- VEGFR2 blockade converts thermally ablative focused ultrasound into a potent driver of T cell-dependent anti-tumor immunity.bioRxiv : the preprint server for biology · 2025Article
- The global status and trends of local ablation for lung malignancies: a bibliometric and visualization analysis.Journal of thoracic disease · 2025Article
- Progress of Immune-Inducible Biomaterials for Post-Ablation Cancers.Advanced healthcare materials · 2025Review
- The Novel Achievements in Oncological Metabolic Radio-Therapy: Isotope Technologies, Targeted Theranostics, Translational Oncology Research.Medical sciences (Basel, Switzerland) · 2025Review
- Multimodality treatment on gastric cancer with liver metastasis: case report.Frontiers in oncology · 2025Article
- Efficacy and Safety of a Therapy Combining Sintilimab and Chemotherapy With Cryoablation in the First-Line Treatment of Advanced Nonsquamous Non-Small Cell Lung Cancer: Protocol for a Phase II, Pilot, Single-Arm, Single-Center Study.JMIR research protocols · 2024Article
- Application of combined ablation and immunotherapy in NSCLC and liver cancer: Current status and future prospects.Heliyon · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe report a 10-year experience in cancer therapy with concomitant treatment of percutaneous thermal ablation (PTA) and immune checkpoint blockers (ICBs). MATERIAL AND
methodsThis retrospective cohort study included all patients at a single tertiary cancer center who had received ICBs at most 90 days before, or 30 days after, PTA. Feasibility and safety were assessed as the primary outcomes. The procedure-related complications and immune-related adverse events (irAEs) were categorized according to the Common Terminology Criteria for Adverse Events v5.0 (CTCAE). Efficacy was evaluated based on overall survival (OS), progression-free survival (PFS), and local progression-free survival (
resultsBetween 2010 and 2021, 78 patients (57% male; median age: 61 years) were included. The PTA modality was predominantly cryoablation (CA) (61%), followed by radiofrequency ablation (RFA) (31%). PTA indications were the treatment of oligo-persistence (29%), oligo-progression (14%), and palliation of symptomatic lesions or prevention of skeletal-related events (SREs) (56%). Most patients received anti-PD1 ICB monotherapy with pembrolizumab (
conclusionsThe concomitant treatment of PTA and ICBs within 2-4 weeks is feasible and safe for both palliative and local control indications. Overall, PTA outcomes were found to be similar to standards for patients not on ICB therapy. While a consistently reproducible abscopal effect remains elusive, the safety profile of concomitant therapy provides the framework for continued assessment as ICB therapies evolve.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.